Gilead hesitant to tout drug for AIDS prevention

Earlier this week researchers found that Gilead's Truvada, a commonly prescribed AIDS drug, prevented monkeys from contracting HIV, igniting hope that the drug could possibly serve as a preventative treatment in those who are at high risk for HIV. Surprisingly, Gilead is reluctant to capitalize on the excitement due to concerns that it will promote unsafe habits among its users. There are a growing number of reports of people experimenting with the off-label use of the drug and the NIH, CDC and the Bill and Melinda Gates Foundation are all bankrolling human trials of Truvada for HIV prevention.

- read this article from the Associated Press for more

Suggested Articles

Wedding Five Prime Therapeutics’ cabiralizumab to Bristol-Myers Squibb’s checkpoint inhibitor Opdivo has proved to be a bust in pancreatic cancer.

Sean Harper and Beth Seidenberg tell FierceBiotech how and why they set up their own VC firm, Westlake Village BioPartners.

Imara is looking to cap a good 2019 with an initial public offering in 2020. The rare disease biotech wants $86 million on the Nasdaq.